Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript

Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.

Seeking Alpha • 17 hours ago

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Zacks Investment Research • 8 hours ago

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.

MarketBeat • a day ago

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53% Consolidated Adjusted EBITDA Attributable to Bausch Health1 of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA1 growth, with 12% Reported and 8% Organic Revenue1 growth and 32% Adjusted EBITDA1 growth Net Income increased $205 million over the prior year Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations1 Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter. "Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth.

PRNewsWire • Oct 28, 2026

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.

Zacks Investment Research • a day ago

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • a day ago

Bausch Health Announces US$50 Million Share Repurchase Program

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program"). The primary objective of the Share Repurchase Program is to manage the potential dilutive impact of future employee equity-based compensation.

PRNewsWire • Oct 28, 2026

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and U9098VAP7 (the "Notes"), using cash on hand.

PRNewsWire • Oct 28, 2026

BHC Q3 Earnings Preview: Here's What You Should Know

Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.

Zacks Investment Research • Oct 26, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.

PRNewsWire • Oct 12, 2026